Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
GBM
MCID: GLB002
MIFTS: 74

Glioblastoma (GBM)

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Glioblastoma

About this section

MalaCards integrated aliases for Glioblastoma:

Name: Glioblastoma 53 59 29 55 6 72
Glioblastoma Multiforme 53 59 72
Gbm 59

Characteristics:

Orphanet epidemiological data:

59
glioblastoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 34
Orphanet: 59  
Rare neurological diseases


External Ids:

MESH via Orphanet 45 D005909
ICD10 via Orphanet 34 C71.9
UMLS via Orphanet 73 C0017636 C1621958
Orphanet 59 ORPHA360
UMLS 72 C0017636 C1621958
Sources

Summaries for Glioblastoma

About this section
NIH Rare Diseases : 53 Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Signs and symptoms, such as headache, nausea, vomiting and/or drowsiness, may develop when the tumor begins to put excess pressure on the brain. Affected people may also experience other features depending on the size and location of the tumor. In most cases, the exact underlying cause is unknown; however, they can rarely occur in people with certain genetic syndromes such as neurofibromatosis type 1, Turcot syndrome and Li Fraumeni syndrome. There is currently no cure for glioblastoma. Treatment is palliative and may include surgery, radiation therapy and/or chemotherapy.

MalaCards based summary : Glioblastoma, also known as glioblastoma multiforme, is related to glioblastoma multiforme and giant cell glioblastoma, and has symptoms including seizures and headache. An important gene associated with Glioblastoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. and TGF-Beta Pathway. The drugs Trametinib and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related phenotypes are glioblastoma multiforme and abnormal cell morphology

Wikipedia : 75 Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins... more...

Sources

Related Diseases for Glioblastoma

About this section

Diseases related to Glioblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 941)
# Related Disease Score Top Affiliating Genes
1 glioblastoma multiforme 36.5 TP53 PTEN PIK3CA MTOR MIR221 MIR21
2 giant cell glioblastoma 36.2 TP53 PTEN IDH1 FGFR1 EGFR BRAF
3 gliosarcoma 35.2 TP53 PTEN IDH1 FGFR1 EGFR
4 glioma 35.1 TP53 PTEN PIK3CA MIR34A MIR296 MIR222
5 gliomatosis cerebri 34.5 TP53 PTEN IDH1 EGFR
6 mismatch repair cancer syndrome 33.9 PTEN PMS2 MSH2
7 brain cancer 33.7 TP53 PTEN PMS2 PIK3CA NRAS MSH2
8 grade iii astrocytoma 32.9 TP53 PTEN EGFR
9 medulloblastoma 32.9 TP53 PTEN PIK3CA NRAS MIR34A IDH1
10 oligodendroglioma 32.8 TP53 PTEN IDH1 EGFR
11 brain glioma 32.6 TP53 IDH1 EGFR
12 breast cancer 32.5 TP53 PTEN PIK3CA MTOR MSH2 MIR34A
13 sarcoma 32.4 TP53 PIK3CA MTOR HRAS BRAF
14 colorectal cancer 32.4 TP53 PTEN PMS2 PIK3CA NRAS MTOR
15 adenocarcinoma 32.4 TP53 PTEN PIK3CA HRAS FGFR1 EGFR
16 pleomorphic xanthoastrocytoma 32.4 TP53 IDH1 BRAF
17 exanthem 32.4 MTOR HRAS EGFR
18 lung cancer susceptibility 3 32.2 TP53 PIK3CA NRAS IDH1 HRAS EGFR
19 hepatocellular carcinoma 32.2 TP53 PTEN PIK3CA NRAS MTOR MIR34A
20 nervous system cancer 32.2 TP53 PTEN IDH1 EGFR
21 central nervous system cancer 32.2 TP53 PTEN IDH1 EGFR
22 melanoma 32.2 TP53 PTEN NRAS MIR34A MIR222 MIR221
23 li-fraumeni syndrome 32.2 TP53 PTEN IDH1 EGFR
24 pancreatic cancer 32.1 TP53 PIK3CA MTOR MIR34A MIR222 MIR221
25 myeloma, multiple 32.1 TP53 NRAS IDH1 HRAS BRAF
26 prostate cancer 32.0 TP53 PTEN PIK3CA MTOR MIR34A MIR296
27 gastric adenocarcinoma 32.0 TP53 PTEN PIK3CA NRAS HRAS FGFR1
28 leukemia, acute myeloid 32.0 TP53 NRAS MTOR MIR222 MIR221 MIR21
29 lung cancer 32.0 TP53 PTEN PIK3CA NRAS MIR34A MIR222
30 bladder cancer 32.0 TP53 MIR222 MIR221 MIR21 HRAS EGFR
31 squamous cell carcinoma 31.9 TP53 PTEN PIK3CA HRAS EGFR BRAF
32 ovarian cancer 31.9 TP53 PTEN PIK3CA MSH2 MIR296 MIR222
33 cholangiocarcinoma 31.9 TP53 PTEN PIK3CA MTOR MIR21 IDH1
34 myelodysplastic syndrome 31.9 TP53 NRAS MIR34A IDH1 HRAS
35 brain stem glioma 31.8 TP53 PIK3CA IDH1 FGFR1 EGFR BRAF
36 cervical cancer 31.8 TP53 PTEN PIK3CA MTOR MIR21 HRAS
37 kidney cancer 31.8 TP53 MTOR MIR21 MIR182
38 breast adenocarcinoma 31.8 TP53 PTEN PIK3CA EGFR
39 gastrointestinal stromal tumor 31.7 TP53 PTEN EGFR BRAF
40 small cell carcinoma 31.7 TP53 PTEN EGFR
41 myeloid leukemia 31.7 TP53 NRAS IDH1 HRAS
42 small cell cancer of the lung 31.7 TP53 PTEN PIK3CA MIR21 EGFR
43 thymoma 31.6 TP53 MTOR HRAS EGFR
44 lynch syndrome 31.6 TP53 PMS2 MSH2 EGFR BRAF
45 squamous cell carcinoma, head and neck 31.5 TP53 PTEN PIK3CA MIR221 MIR21 HRAS
46 leukemia, acute lymphoblastic 31.5 MIR222 MIR221 MIR21
47 adenoid cystic carcinoma 31.5 TP53 PTEN PIK3CA IDH1 HRAS BCOR
48 supratentorial cancer 31.5 TP53 PTEN IDH1 EGFR
49 colorectal adenocarcinoma 31.4 TP53 MSH2 HRAS EGFR BRAF
50 testicular germ cell tumor 31.4 TP53 PTEN MSH2 HRAS BRAF

Graphical network of the top 20 diseases related to Glioblastoma:



Diseases related to Glioblastoma
Sources

Symptoms & Phenotypes for Glioblastoma

About this section

Human phenotypes related to Glioblastoma:

32 59 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 glioblastoma multiforme 32 obligate (100%) HP:0012174
2 abnormal cell morphology 59 32 hallmark (90%) Very frequent (99-80%) HP:0025461
3 muscle weakness 59 32 frequent (33%) Frequent (79-30%) HP:0001324
4 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
5 visual loss 59 32 frequent (33%) Frequent (79-30%) HP:0000572
6 paralysis 59 32 frequent (33%) Frequent (79-30%) HP:0003470
7 headache 59 32 frequent (33%) Frequent (79-30%) HP:0002315
8 cerebral edema 59 32 frequent (33%) Frequent (79-30%) HP:0002181
9 language impairment 59 32 frequent (33%) Frequent (79-30%) HP:0002463
10 abnormal corpus callosum morphology 59 32 frequent (33%) Frequent (79-30%) HP:0001273
11 mood changes 59 32 frequent (33%) Frequent (79-30%) HP:0001575
12 seizures 59 32 occasional (7.5%) Occasional (29-5%) HP:0001250
13 memory impairment 59 32 occasional (7.5%) Occasional (29-5%) HP:0002354
14 abnormality of nervous system physiology 59 Frequent (79-30%)
15 abnormality of the cerebral white matter 59 Frequent (79-30%)
16 glioblastoma 59 Obligate (100%)

UMLS symptoms related to Glioblastoma:


seizures, headache

GenomeRNAi Phenotypes related to Glioblastoma according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.56 EGFR HRAS MTOR PIK3CA BRAF
2 Decreased viability GR00221-A-1 10.56 EGFR FGFR1 HRAS MTOR NRAS PIK3CA
3 Decreased viability GR00221-A-2 10.56 FGFR1 HRAS PIK3CA
4 Decreased viability GR00221-A-3 10.56 HRAS NRAS
5 Decreased viability GR00221-A-4 10.56 EGFR MTOR PIK3CA BRAF
6 Decreased viability GR00301-A 10.56 BRAF
7 Decreased viability GR00342-S-1 10.56 MTOR
8 Decreased viability GR00342-S-2 10.56 MTOR
9 Decreased viability GR00381-A-1 10.56 BRAF
10 Decreased viability GR00402-S-2 10.56 EGFR FGFR1 HRAS MTOR NRAS PIK3CA
11 Decreased cell migration GR00055-A-1 9.72 BRAF EGFR HRAS MTOR PIK3CA
12 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.65 EGFR HRAS MTOR NRAS PTEN
13 Decreased viability with paclitaxel GR00179-A-1 9.35 EGFR MTOR
14 Decreased viability with paclitaxel GR00179-A-2 9.35 MTOR
15 Decreased viability with paclitaxel GR00179-A-3 9.35 EGFR MTOR
16 Increased cell migration GR00055-A-3 9.02 BRAF EGFR HRAS MTOR PIK3CA

MGI Mouse Phenotypes related to Glioblastoma:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.28 BCOR BRAF EGFR FGFR1 MSH2 MTOR
2 cardiovascular system MP:0005385 10.25 BCOR BRAF EGFR FGFR1 HRAS MTOR
3 homeostasis/metabolism MP:0005376 10.23 BRAF EGFR FGFR1 HRAS IDH1 MSH2
4 hematopoietic system MP:0005397 10.22 BCOR BRAF EGFR FGFR1 IDH1 MSH2
5 immune system MP:0005387 10.21 BCOR BRAF EGFR FGFR1 IDH1 MSH2
6 endocrine/exocrine gland MP:0005379 10.19 BRAF EGFR FGFR1 HRAS MTOR NRAS
7 digestive/alimentary MP:0005381 10.18 BRAF EGFR FGFR1 HRAS MSH2 NRAS
8 mortality/aging MP:0010768 10.18 BCOR BRAF EGFR FGFR1 HRAS IDH1
9 embryo MP:0005380 10.16 BCOR BRAF EGFR FGFR1 MTOR NRAS
10 integument MP:0010771 10.06 BRAF EGFR FGFR1 HRAS MSH2 NRAS
11 neoplasm MP:0002006 9.97 BRAF EGFR HRAS MSH2 NRAS PIK3CA
12 no phenotypic analysis MP:0003012 9.8 EGFR FGFR1 HRAS MTOR NRAS PIK3CA
13 pigmentation MP:0001186 9.55 BRAF EGFR NRAS PTEN TP53
14 renal/urinary system MP:0005367 9.5 BRAF EGFR FGFR1 HRAS MTOR PTEN
15 skeleton MP:0005390 9.32 BRAF EGFR FGFR1 HRAS IDH1 MTOR
Sources

Drugs & Therapeutics for Glioblastoma

About this section

Drugs for Glioblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 619)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trametinib Approved Phase 4 871700-17-3 11707110
2
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
5
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
6
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
7
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
8
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
9
Trioxsalen Approved Phase 3 3902-71-4 5585
10
Donepezil Approved Phase 3 120014-06-4 3152
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
13
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
14
Iodine Approved, Investigational Phase 3 7553-56-2 807
15
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
16
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
17
Etoposide Approved Phase 3 33419-42-0 36462
18
Streptozocin Approved, Investigational Phase 2, Phase 3 18883-66-4 29327
19
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
20
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
21
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
22
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
23
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
24
Povidone Approved Phase 3 9003-39-8
25
Povidone-iodine Approved Phase 3 25655-41-8
26
Flucytosine Approved, Investigational Phase 2, Phase 3 2022-85-7 3366
27
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
28
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 5281106 54677470
29
Hydroxychloroquine Approved Phase 2, Phase 3 118-42-3 3652
30
Carmustine Approved, Investigational Phase 3 154-93-8 2578
31
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
32
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
33
Histamine Approved, Investigational Phase 3 51-45-6 774
34
Norepinephrine Approved Phase 3 51-41-2 439260
35
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
36
Cyproheptadine Approved Phase 3 129-03-3 2913
37
Serine Approved, Nutraceutical Phase 3 56-45-1 5951
38
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
39
Nimotuzumab Investigational Phase 3 780758-10-3, 828933-61-3
40
Rindopepimut Investigational Phase 3 1108208-65-6
41 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
42
Semustine Experimental, Investigational Phase 2, Phase 3 13909-09-6
43 Dianhydrogalactitol Investigational Phase 3 23261-20-3
44
Veliparib Investigational Phase 2, Phase 3 912444-00-9 11960529
45 Antiparkinson Agents Phase 2, Phase 3
46 Serine Proteinase Inhibitors Phase 3
47 Parasympatholytics Phase 2, Phase 3
48 Muscarinic Antagonists Phase 2, Phase 3
49 Cholinergic Antagonists Phase 2, Phase 3
50 Anesthetics, General Phase 3

Interventional clinical trials:

(show top 50) (show all 1512)
# Name Status NCT ID Phase Drugs
1 A Clinical Study of Standard TEMODAL® Regimen Versus Standard Regimen Plus Early Post-Surgery TEMODAL® Chemotherapy in Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00686725 Phase 4 Temozolomide
2 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
3 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Not yet recruiting NCT03975829 Phase 4 dabrafenib;trametinib
4 A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient Terminated NCT01756729 Phase 4
5 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
6 Phase II Prospective Study of Sequential Myeloablative Chemotherapy With Stem Cell Rescue for the Treatment of Selected High Risk CNS Tumors and Recurrent CNS Tumors Unknown status NCT00179803 Phase 2, Phase 3
7 Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma- A Randomized Multicenter Trial Unknown status NCT01805453 Phase 3 Losartan;Placebo
8 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
9 Randomized, Prospective, Multicenter Blinding Singles With Arm A and Arm B Innovative Strategy Strategy Conventional Unknown status NCT01811121 Phase 3 5-aminolévulinique acid (5-ALA);Placebo
10 PHASE I-II TRIAL OF METRONOMIC TEMOZOLAMIDE WITH INTERMITTENT INTENSIFICATION AND IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
11 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
12 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
13 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
14 A Phase III, Randomized, Open-Label Study Of IV Edotecarin Vs Temozolomide Or Carmustine (BCNU) Or Lomustine (CCNU) In Patients With Glioblastoma Multiforme At First Relapse After Alkylator-Based (NEO) Adjuvant Chemotherapy Completed NCT00068952 Phase 3 Edotecarin;Temozolomide;Carmustine (BCNU);Lomustine (CCNU)
15 Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma Completed NCT00295815 Phase 3 enzastaurin;lomustine
16 Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant OSAG 101 (Theraloc®) Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV Completed NCT00753246 Phase 3 nimotuzumab
17 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
18 A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme Completed NCT00088400 Phase 3 TransMID
19 A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME Completed NCT00002545 Phase 3 carmustine
20 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
21 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
22 Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study Completed NCT00006353 Phase 3 temozolomide
23 A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
24 A Randomized Phase III Study of Short Course (One-week) Radiation Therapy Versus Standard Course (Three-week) Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT01450449 Phase 3
25 A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma Completed NCT00335075 Phase 3 Temozolomide;Semustine
26 A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Completed NCT00482677 Phase 3 temozolomide
27 A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
28 Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial Completed NCT00224978 Phase 3 Chloroquine
29 A Prospective, Multi-center Trial of NovoTTF-100A Compared to Best Standard of Care in Patients With Progressive or Recurrent GBM Completed NCT00379470 Phase 3
30 A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM. Completed NCT00916409 Phase 3 Temozolomide
31 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
32 A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
33 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
34 A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma Completed NCT02511405 Phase 3 VB-111 + bevacizumab;Bevacizumab
35 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
36 Multi-center, Randomized, Open-label Phase 3 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
37 A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTINâ„¢, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone Completed NCT00777153 Phase 3 Cediranib;Cediranib;Lomustine Chemotherapy;Placebo Cediranib
38 An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
39 Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC) Completed NCT00689221 Phase 3 Cilengitide;Temozolomide
40 Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem) Completed NCT01502241 Phase 3 Temozolomide
41 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
42 Phase III Trial of CCNU/Temozolomide (TMZ) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT-methylated Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
43 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
44 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
45 Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
46 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
47 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
48 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
49 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
50 A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II) Recruiting NCT02685605 Phase 3 Temozolomide

Search NIH Clinical Center for Glioblastoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Bevacizumab
Carmustine
Carmustine
Irinotecan
Sources

Genetic Tests for Glioblastoma

About this section

Genetic tests related to Glioblastoma:

# Genetic test Affiliating Genes
1 Glioblastoma 29
Sources

Anatomical Context for Glioblastoma

About this section

MalaCards organs/tissues related to Glioblastoma:

41
Brain, T Cells, Endothelial, Testes, Breast, Lung, Spinal Cord
Sources

Publications for Glioblastoma

About this section

Articles related to Glioblastoma:

(show top 50) (show all 30623)
# Title Authors PMID Year
1
MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. 9 38 88
19773441 2009
2
Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. 9 38 88
17721077 2007
3
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. 38 88
20227367 2010
4
miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors. 38 88
19159078 2009
5
MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. 38 88
19013014 2008
6
MIR-451 and Imatinib mesylate inhibit tumor growth of Glioblastoma stem cells. 38 88
18765229 2008
7
MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. 38 88
18829576 2008
8
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. 38 88
18577219 2008
9
Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. 71
16825431 2007
10
Extensive modulation of a set of microRNAs in primary glioblastoma. 38 88
16039986 2005
11
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. 38 88
16024602 2005
12
Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. 71
15689453 2005
13
Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. 71
14670928 2004
14
miR-182 as a prognostic marker for glioma progression and patient survival. 88
20472885 2010
15
Effect of combination treatment of rapamycin and isoflavones on mTOR pathway in human glioblastoma (U87) cells. 9 38
20177775 2010
16
Knockdown of STAT3 expression by RNAi suppresses growth and induces apoptosis and differentiation in glioblastoma stem cells. 9 38
20514402 2010
17
IL-27 inhibits OSM-mediated TNF-alpha and iNOS gene expression in microglia. 9 38
20468050 2010
18
Prognostic value of MGMT promoter methylation in glioblastoma patients treated with temozolomide-based chemoradiation: a Portuguese multicentre study. 9 38
20428822 2010
19
Mangiferin, a naturally occurring glucoxilxanthone improves long-term object recognition memory in rats. 9 38
20303935 2010
20
Epidermal growth factor receptor in glioblastomas: correlation between gene copy number and protein expression. 9 38
20303140 2010
21
Influence of Etoposide on anti-apoptotic and multidrug resistance-associated protein genes in CD133 positive U251 glioblastoma stem-like cells. 9 38
20388502 2010
22
New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile. 9 38
20305620 2010
23
Amplicons on chromosome 12q13-21 in glioblastoma recurrences. 9 38
19839052 2010
24
A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage. 9 38
20022592 2010
25
Differential expression and cellular distribution of gamma-tubulin and betaIII-tubulin in medulloblastomas and human medulloblastoma cell lines. 9 38
20162618 2010
26
Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. 9 38
20372840 2010
27
Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation. 9 38
20199106 2010
28
Hepatocyte growth factor in cerebrospinal fluid is associated with mortality and recurrence of glioblastoma, and could be of prognostic value. 9 38
19856144 2010
29
Opposite changes in cannabinoid CB1 and CB2 receptor expression in human gliomas. 9 38
20307616 2010
30
Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma. 9 38
20309962 2010
31
Differential role of cathepsins B and L in autophagy-associated cell death induced by arsenic trioxide in U87 human glioblastoma cells. 9 38
20302512 2010
32
The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. 9 38
19937366 2010
33
Integrin alpha 6: anchors away for glioma stem cells. 9 38
20452311 2010
34
Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival. 9 38
19810093 2010
35
AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth. 9 38
20423992 2010
36
Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A3 adenosine receptors. 9 38
20096265 2010
37
Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. 9 38
19841865 2010
38
Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression. 9 38
20457618 2010
39
Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. 9 38
20457619 2010
40
Integrin alpha 6 regulates glioblastoma stem cells. 9 38
20452317 2010
41
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. 9 38
20171141 2010
42
Farnesyl diphosphate synthase attenuates paclitaxel-induced apoptotic cell death in human glioblastoma U87MG cells. 9 38
20298756 2010
43
Development of a predictor for human brain tumors based on gene expression values obtained from two types of microarray technologies. 9 38
20235875 2010
44
Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. 9 38
20436671 2010
45
A novel molecular diagnostic of glioblastomas: detection of an extracellular fragment of protein tyrosine phosphatase mu. 9 38
20360941 2010
46
Prion protein: From physiology to cancer biology. 9 38
19674833 2010
47
Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo. 9 38
20140015 2010
48
Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3. 9 38
20371721 2010
49
Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. 9 38
20308316 2010
50
Tumor vessel biology in pediatric intracranial ependymoma. 9 38
20367336 2010
Sources

Variations for Glioblastoma

About this section

ClinVar genetic disease variations for Glioblastoma:

6 (show top 50) (show all 230)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 H3-3A NM_002107.6(H3-3A): c.103G> A (p.Gly35Arg) single nucleotide variant other rs1553260624 1:226252155-226252155 1:226064454-226064454
2 MED12 NM_005120.3(MED12): c.5980C> T (p.Arg1994Trp) single nucleotide variant other rs1556339256 X:70357729-70357729 X:71137879-71137879
3 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
4 PIK3CA NM_006218.4(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
5 NRAS NM_002524.5(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
6 BRAF NM_004333.6(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic rs113488022 7:140453136-140453136 7:140753336-140753336
7 BRAF NM_004333.6(BRAF): c.1787G> T (p.Gly596Val) single nucleotide variant Pathogenic rs397507483 7:140453148-140453148 7:140753348-140753348
8 EGFR NM_005228.5(EGFR): c.2156G> C (p.Gly719Ala) single nucleotide variant Pathogenic rs121913428 7:55241708-55241708 7:55174015-55174015
9 PIK3CA NM_006218.4(PIK3CA): c.1637A> G (p.Gln546Arg) single nucleotide variant Pathogenic rs397517201 3:178936095-178936095 3:179218307-179218307
10 PMS2 NM_000535.7(PMS2): c.1831dup (p.Ile611fs) duplication Pathogenic rs63750250 7:6026565-6026565 7:5986934-5986934
11 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic rs587778720 17:7578211-7578211 17:7674893-7674893
12 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic rs28934574 17:7577094-7577094 17:7673776-7673776
13 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic rs587781525 17:7577096-7577096 17:7673778-7673778
14 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
15 MTOR NM_004958.4(MTOR): c.4448G> T (p.Cys1483Phe) single nucleotide variant Pathogenic rs786205165 1:11217230-11217230 1:11157173-11157173
16 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic rs760043106 17:7578265-7578265 17:7674947-7674947
17 NRAS NM_002524.5(NRAS): c.182A> C (p.Gln61Pro) single nucleotide variant Pathogenic rs11554290 1:115256529-115256529 1:114713908-114713908
18 BCOR NM_001123383.1(BCOR): c.3779_3780AG[1] (p.Leu1262fs) short repeat Pathogenic rs886042842 X:39922288-39922289 X:40063035-40063036
19 MSH2 NM_000251.2(MSH2): c.1958_1965del (p.Asn653fs) deletion Pathogenic 2:47702362-47702369 2:47475223-47475230
20 PIK3CA NM_006218.4(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic rs121913281 3:178952084-178952084 3:179234296-179234296
21 PIK3CA NM_006218.4(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
22 HRAS NM_005343.4(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
23 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic rs121912655 17:7577556-7577556 17:7674238-7674238
24 NRAS NM_002524.5(NRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic rs121913255 1:115256528-115256528 1:114713907-114713907
25 PTEN NM_000314.7(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic rs121909224 10:89692904-89692904 10:87933147-87933147
26 TP53 NM_000546.5(TP53): c.712T> C (p.Cys238Arg) single nucleotide variant Pathogenic rs1057519981 17:7577569-7577569 17:7674251-7674251
27 TP53 NM_000546.5(TP53): c.713G> T (p.Cys238Phe) single nucleotide variant Pathogenic rs730882005 17:7577568-7577568 17:7674250-7674250
28 TP53 NM_000546.5(TP53): c.841G> T (p.Asp281Tyr) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
29 TP53 NM_000546.5(TP53): c.841G> A (p.Asp281Asn) single nucleotide variant Pathogenic rs764146326 17:7577097-7577097 17:7673779-7673779
30 TP53 NM_000546.5(TP53): c.537T> G (p.His179Gln) single nucleotide variant Pathogenic rs876660821 17:7578393-7578393 17:7675075-7675075
31 TP53 NM_000546.5(TP53): c.818G> T (p.Arg273Leu) single nucleotide variant Pathogenic rs28934576 17:7577120-7577120 17:7673802-7673802
32 PTEN NM_000314.7(PTEN): c.697C> T (p.Arg233Ter) single nucleotide variant Pathogenic rs121909219 10:89717672-89717672 10:87957915-87957915
33 PTEN NM_000314.7(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic rs121909229 10:89692905-89692905 10:87933148-87933148
34 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic rs121912651 17:7577539-7577539 17:7674221-7674221
35 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic rs28934575 17:7577548-7577548 17:7674230-7674230
36 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic rs121912656 17:7577547-7577547 17:7674229-7674229
37 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic rs121912666 17:7578190-7578190 17:7674872-7674872
38 HRAS NM_005343.4(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 11:534289-534289 11:534289-534289
39 HRAS NM_005343.4(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic rs104894230 11:534288-534288 11:534288-534288
40 PIK3CA NM_006218.4(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic rs121913279 3:178952085-178952085 3:179234297-179234297
41 PIK3CA NM_006218.4(PIK3CA): c.1636C> G (p.Gln546Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 3:178936094-178936094 3:179218306-179218306
42 PIK3CA NM_006218.4(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 3:178936091-178936091 3:179218303-179218303
43 PIK3CA NM_006218.4(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 3:178936092-178936092 3:179218304-179218304
44 PIK3CA NM_006218.4(PIK3CA): c.1636C> A (p.Gln546Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913286 3:178936094-178936094 3:179218306-179218306
45 TP53 NM_000546.5(TP53): c.700T> C (p.Tyr234His) single nucleotide variant Pathogenic/Likely pathogenic rs864622237 17:7577581-7577581 17:7674263-7674263
46 TP53 NM_000546.5(TP53): c.817C> A (p.Arg273Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913343 17:7577121-7577121 17:7673803-7673803
47 TP53 NM_000546.5(TP53): c.845G> C (p.Arg282Pro) single nucleotide variant Pathogenic/Likely pathogenic rs730882008 17:7577093-7577093 17:7673775-7673775
48 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 17:7578407-7578407 17:7675089-7675089
49 TP53 NM_000546.5(TP53): c.730G> A (p.Gly244Ser) single nucleotide variant Pathogenic/Likely pathogenic rs1057519989 17:7577551-7577551 17:7674233-7674233
50 PIK3CA NM_006218.4(PIK3CA): c.1030G> A (p.Val344Met) single nucleotide variant Pathogenic/Likely pathogenic rs1057519942 3:178921548-178921548 3:179203760-179203760

Copy number variations for Glioblastoma from CNVD:

7 (show all 37)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13758 1 1 28000000 Copy number Glioblastoma
2 30312 1 241718157 242073207 Amplification AKT3 Glioblastoma
3 33636 1 46800000 50700000 Copy number Glioblastoma
4 40021 10 123227833 123347962 Amplification FGFR2 Glioblastoma
5 42796 10 40200000 135534747 Loss Glioblastoma
6 51519 11 127400000 130300000 Loss Glioblastoma
7 70074 12 58100000 63100000 Copy number CDK4 Glioblastoma
8 71138 12 67700000 71500000 Copy number MDM2 Glioblastoma
9 74585 13 109204184 109236915 Amplification IRS2 Glioblastoma
10 87860 14 78400000 100400000 Loss Glioblastoma
11 106844 17 1 3600000 Loss Glioblastoma
12 109487 17 26446120 26728821 Deletion NF1 Glioblastoma
13 122049 18 52000000 76117153 Loss Glioblastoma
14 132099 19 57600000 63811651 Gain Glioblastoma
15 133731 19 6900000 13900000 Copy number CDKN2D Glioblastoma
16 137039 2 136600000 209100000 Gain Glioblastoma
17 187590 4 52700000 59500000 Amplification CHIC2 Glioblastoma
18 187591 4 52700000 59500000 Amplification IGFBP7 Glioblastoma
19 187592 4 52700000 59500000 Amplification KDR Glioblastoma
20 187593 4 52700000 59500000 Amplification KIT Glioblastoma
21 187594 4 52700000 59500000 Amplification KIT Glioblastoma
22 187596 4 52700000 59500000 Amplification LNX1 Glioblastoma
23 187597 4 52700000 59500000 Amplification PDGFRA Glioblastoma
24 187598 4 52700000 59500000 Amplification PDGFRA Glioblastoma
25 187599 4 52700000 59500000 Amplification RASL11B Glioblastoma
26 187600 4 52700000 59500000 Amplification REST Glioblastoma
27 187601 4 52700000 59500000 Amplification SEC3L1 Glioblastoma
28 187602 4 52700000 59500000 Amplification USP46 Glioblastoma
29 187603 4 52700000 59500000 Amplification VEGFR2 Glioblastoma
30 187604 4 52700000 59500000 Copy number Glioblastoma
31 207847 6 161688579 163068824 Deletion PARK2 Glioblastoma
32 226025 7 54000000 58000000 Copy number EGFR Glioblastoma
33 226576 7 59600001 66100000 Gain Glioblastoma
34 250055 9 19900000 33200000 Copy number CDKN2A Glioblastoma
35 253823 9 4600000 14200000 Deletion PTPRD Glioblastoma
36 253952 9 49000000 141213431 Loss Glioblastoma
37 255680 9 8304245 10602723 Deletion PTPRD Glioblastoma
Sources

Expression for Glioblastoma

About this section
Search GEO for disease gene expression data for Glioblastoma.
Sources

Pathways for Glioblastoma

About this section

Pathways related to Glioblastoma according to GeneCards Suite gene sharing:

(show top 50) (show all 109)
# Super pathways Score Top Affiliating Genes
1
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 66
Show member pathways
 13.64 TP53 PIK3CA NRAS MTOR MIR21 MIR182
2
TGF-Beta Pathway 64
Show member pathways
 13.62 TP53 PIK3CA NRAS MTOR HRAS FGFR1
3
Class I MHC mediated antigen processing and presentation 66
Show member pathways
 13.54 TP53 PTEN PIK3CA NRAS MTOR HRAS
4
Cytokine Signaling in Immune system 66
Show member pathways
 13.43 TP53 PIK3CA NRAS HRAS FGFR1 EGFR
5
IL-2 Pathway 64
Show member pathways
 13.29 TP53 PTEN NRAS MTOR HRAS EGFR
6
Phospholipase-C Pathway 64
Show member pathways
 13.17 TP53 PTEN NRAS MTOR HRAS FGFR1
7
PI3K-Akt signaling pathway 37
Show member pathways
 13.09 TP53 PTEN PIK3CA NRAS MTOR HRAS
8
Human cytomegalovirus infection 37
Show member pathways
 13.07 TP53 PTEN PIK3CA NRAS MTOR HRAS
9
TNFR1 Pathway 64
Show member pathways
 13.06 TP53 PTEN PIK3CA NRAS MTOR HRAS
10
Regulation of lipid metabolism Insulin signaling-generic cascades 22
Show member pathways
 13.02 PTEN PIK3CA NRAS MTOR HRAS EGFR
11
Development Angiotensin activation of ERK 22
Show member pathways
 13 TP53 PIK3CA NRAS HRAS EGFR BRAF
12
Focal Adhesion 37 1
Show member pathways
 12.99 PTEN PIK3CA NRAS HRAS EGFR BRAF
13
NFAT and Cardiac Hypertrophy 64
Show member pathways
 12.97 PTEN PIK3CA NRAS MTOR HRAS FGFR1
14
Endometrial cancer 37
Show member pathways
 12.9 TP53 PTEN PIK3CA NRAS MTOR MSH2
15
MAPK signaling pathway 37 1
12.87 TP53 NRAS HRAS FGFR1 EGFR BRAF
16
Common Cytokine Receptor Gamma-Chain Family Signaling Pathways 65
Show member pathways
 12.85 PTEN PIK3CA MTOR HRAS BRAF
17
Ras signaling pathway 37
Show member pathways
 12.84 PIK3CA NRAS HRAS FGFR1 EGFR BRAF
18
Pathways in cancer 37
12.83 TP53 PTEN PIK3CA NRAS MTOR MSH2
19
Development HGF signaling pathway 22
Show member pathways
 12.82 TP53 PTEN PIK3CA NRAS MTOR HRAS
20
Gastric cancer 37
Show member pathways
 12.8 TP53 PTEN PIK3CA NRAS MTOR HRAS
21
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.78 PTEN PIK3CA NRAS MTOR HRAS EGFR
22
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.78 TP53 PTEN PIK3CA NRAS MTOR HRAS
23
4-1BB Pathway 64
Show member pathways
 12.76 TP53 NRAS HRAS EGFR BRAF
24
Regulation of actin cytoskeleton 37 1
12.75 PIK3CA NRAS HRAS FGFR1 EGFR BRAF
25
Glioma 37
Show member pathways
 12.74 TP53 PTEN PIK3CA NRAS MTOR HRAS
26
Immune response IL-23 signaling pathway 22
Show member pathways
 12.71 TP53 PIK3CA NRAS MSH2 HRAS EGFR
27
ErbB signaling pathway 37 1
Show member pathways
 12.68 TP53 PIK3CA NRAS MTOR HRAS EGFR
28
Negative regulation of FGFR1 signaling 66
Show member pathways
 12.67 PIK3CA NRAS HRAS FGFR1 BRAF
29
Prolactin Signaling Pathway 1 37
Show member pathways
 12.59 PTEN PIK3CA NRAS MTOR HRAS
30
MET promotes cell motility 66
Show member pathways
 12.53 PIK3CA NRAS MTOR HRAS
31
Phospholipase D signaling pathway 37
Show member pathways
 12.52 PIK3CA NRAS MTOR HRAS EGFR
32
JAK-STAT signaling pathway (KEGG) 37
Show member pathways
 12.51 PIK3CA NRAS MTOR HRAS EGFR
33
Development IGF-1 receptor signaling 22
Show member pathways
 12.51 TP53 PTEN PIK3CA MTOR HRAS
34
B cell receptor signaling pathway (KEGG) 1
Show member pathways
 12.51 PTEN PIK3CA NRAS HRAS BRAF
35
G-protein signaling RAC1 in cellular process 22
Show member pathways
 12.51 PIK3CA NRAS MTOR HRAS FGFR1 EGFR
36
Apoptosis Pathway 71
Show member pathways